Jonathan M. Lehman
AstraZeneca (United States) · 68 works · 2,483 citations · h-index 16
Top works
- Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
- Directional Cell Migration and Chemotaxis in Wound Healing Response to PDGF-AA are Coordinated by the Primary Cilium in Fibroblasts
- New Approaches to SCLC Therapy: From the Laboratory to the Clinic
- The Oak Ridge Polycystic Kidney mouse: Modeling ciliopathies of mice and men
- Single cell analysis of human tissues and solid tumors with mass cytometry
- Single Cell Analysis of Human Tissues and Solid Tumors with Mass Cytometry
- An Essential Role for Dermal Primary Cilia in Hair Follicle Morphogenesis
- Role of epidermal primary cilia in the homeostasis of skin and hair follicles
- Somatostatin receptor 2 signaling promotes growth and tumor survival in small‐cell lung cancer
- A Phase 1–2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC
- 68Ga-DOTATATE PET/CT imaging of indeterminate pulmonary nodules and lung cancer
- Somatostatin receptor 2 targeting in small cell lung carcinoma: perspectives
- Author Correction: Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
- Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope
- Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group
- HLA-DR cancer cells expression correlates with T cell infiltration and is enriched in lung adenocarcinoma with indolent behavior
- Penetrance and Expressivity of Genes Involved in the Development of Epilepsy in the Genetically Epilepsy-Prone Rat (GEPR)
- Virus cell interactions analyzed with flow cytometry
- Ph1/2 study of Rova-T in combination with nivolumab (Nivo) ± ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC.
- Integrated Multi-omics Analysis of Early Lung Adenocarcinoma Links Tumor Biological Features with Predicted Indolence or Aggressiveness